Search Results - "Biezen, Eveline den"

Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer by Inda, Márcia A, Blok, Erik J, Kuppen, Peter J K, Charehbili, Ayoub, den Biezen-Timmermans, Eveline C, van Brussel, Anne, Fruytier, Sevgi E, Meershoek-Klein Kranenbarg, Elma, Kloet, Susan, van der Burg, Bart, Martens, John W M, Sims, Andrew H, Turnbull, Arran K, Dixon, J Michael, Verhaegh, Wim, Kroep, Judith R, van de Velde, Cornelis J H, van de Stolpe, Anja

“…Endocrine therapy is important for management of patients with estrogen receptor (ER)-positive breast cancer; however, positive ER staining does not reliably…”
Get full text

Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen-receptor pathway inhibitors by Menssouri, Naoual, Poiraudeau, Loic, Helissey, Carole, Bigot, Ludovic, Sabio, Jonathan, Ibrahim, Tony, Pobel, Cedric, Nicotra, Claudio, Ngo-Camus, Maud, Lacroix, Ludovic, Rouleau, Etienne, Tselikas, Lambros, Chauchereau, Anne, Blanc-Durand, Félix, Bernard-Tessier, Alice, Patrikidou, Anna, Naoun, Natacha, Flippot, Ronan, Colomba, Emeline, Fuerea, Alina, Albiges, Laurence, Lavaud, Pernelle, van de Wiel, Paul, den Biezen-Timmermans, Eveline, Wesseling-Rozendaal, Yvonne, Ponce-Aix, Santiago, Michiels, Stefan, Massard, Christophe, Gautheret, Daniel, Barlesi, Fabrice, Andre, Fabrice, Besse, Benjamin, Scoazec, Jean-Yves, Friboulet, Luc, Fizazi, Karim, Loriot, Yohann

“…The androgen receptor axis inhibitors (ARPI) (e.g, enzalutamide, abiraterone acetate) are administered in daily practice for men with metastatic…”
Get full text

The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes by Schlomm, Thorsten, Heitkötter, Birthe, Bögemann, Martin, Houslay, Miles D., Bangma, Chris, Semjonow, Axel, Hoffmann, Ralf, Tennstedt, Pierre, Baillie, George S., Wrobel, Janneke, van Brussel, Anne, den Biezen-Timmermans, Eveline, Vos, Pieter C., de Witz, Christiane, van Strijp, Dianne, Huss, Sebastian

“…Purpose. To further validate the prognostic power of the biomarker PDE4D7, we investigated the correlation of PDE4D7 scores adjusted for presurgical clinical…”
Get full text

Abstract 533: Breast cancer IHC subtypes display heterogenous and independent targetable signaling pathway activity profiles by Magliocco, Anthony M., van de Stolpe, Anja, Akse, Martijn, den Biezen, Eveline, Holtzer, Laurent

“…Abstract Background: Primary breast cancer is routinely subtyped using immunohistochemistry (IHC) staining and treatment choice is guided by the subtype…”
Get full text

Abstract 740: A robust rapid mRNA based test to profile simultaneously ER, AR, PI3K and MAPK functional signaling pathway activity for precision oncology by den Biezen, Eveline, Vermeer, Saskia, Keizer, Diederick, Akse, Martijn, van Zelst, Martijn, van Strijp, Dianne, Park, Hannah, Magliocco, Anthony

“…Abstract Introduction: OncoSignal test was developed to determine and quantify functional signal transduction pathway activity levels of 4 key oncogenic…”
Get full text

Abstract P2-08-18: Evaluation of the activity of key actionable oncogenic driving pathways in triple negative breast cancer using OncoSignal™; a novel molecular assay based on transcriptional profile analysis by Magliocco, Genevra, den Biezen, Eveline, Keizer, Diederick, Akse, Martijn, van Zelst, Martijn, van Strijp, Dianne, Vermeer, Saskia, van de Stolpe, Anja, Magliocco, Anthony

“…Abstract Introduction: Triple negative breast cancer (TNBC), defined by the absence of expression of estrogen receptor (ER), progesterone receptor, and HER2,…”
Get full text

Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors by Menssouri, Naoual, Poiraudeau, Loïc, Helissey, Carole, Bigot, Ludovic, Sabio, Jonathan, Ibrahim, Tony, Pobel, Cédric, Nicotra, Claudio, Ngo-Camus, Maud, Lacroix, Ludovic, Rouleau, Etienne, Tselikas, Lambros, Chauchereau, Anne, Blanc-Durand, Félix, Bernard-Tessier, Alice, Patrikidou, Anna, Naoun, Natacha, Flippot, Ronan, Colomba, Emeline, Fuerea, Alina, Albiges, Laurence, Lavaud, Pernelle, van de Wiel, Paul, den Biezen, Eveline, Wesseling-Rozendaal, Yvonne, Ponce-Aix, Santiago, Michiels, Stefan, Massard, Christophe, Gautheret, Daniel, Barlesi, Fabrice, André, Fabrice, Besse, Benjamin, Scoazec, Jean-Yves, Friboulet, Luc, Fizazi, Karim, Loriot, Yohann

“…Abstract Purpose: The androgen receptor axis inhibitors (ARPI; e.g., enzalutamide, abiraterone acetate) are administered in daily practice for men with…”
Get full text

Abstract 3690: Measuring functional signal transduction pathway activity on breast cancer tissue samples to determine intra-tumor heterogeneity and heterogeneity between primary and metastatic tumors by Stolpe, Anja Van De, Brussel, Anne van, Moelans, Cathy, Inda, Marcia A., Verhaegh, Wim, Biezen, Eveline den, Diest, Paul van

“…Abstract Background Treatment with targeted drugs is increasingly used in breast cancer aiming to block the tumor driving pathway(s). Drug choice is often…”
Get full text

Abstract 6221: Support for targeted therapy selection in triple negative breast cancer patients using aberrant signal transduction pathway activity profiles by Keizer, Diederick M., Wesseling, Yvonne J., van Strijp, Dianne A., Vermeer, Saskia M., den Biezen, Eveline C.

“…Abstract Introduction: Success of therapeutic interventions largely rely on the pathological and biological characteristics of the tumor and varies due to the…”
Get full text

Heterogeneity in Signaling Pathway Activity within Primary and between Primary and Metastatic Breast Cancer by Inda, Márcia A, van Swinderen, Paul, van Brussel, Anne, Moelans, Cathy B, Verhaegh, Wim, van Zon, Hans, den Biezen, Eveline, Bikker, Jan Willem, van Diest, Paul J, van de Stolpe, Anja

“…Targeted therapy aims to block tumor-driving signaling pathways and is generally based on analysis of one primary tumor (PT) biopsy. Tumor heterogeneity within…”
Get full text

Analysis of signaling pathway activity in desmoid-type fibromatosis (DF) to identify druggable pathways by Van De Stolpe, Anja, Akse, Martijn, den Biezen-Timmermans, Eveline, Blay, Jean-Yves, Penel, Nicolas

“…Abstract only e23558 Background: DF are locally invasive soft tissue tumors of fibroblast origin, with unpredictable course. CTTNB1 mutations are a hallmark of…”
Get full text

Abstract 2645: Quantitative measurement of multiple signal transduction pathway activities in cell and tissue culture, including cancer, fibroblast, and immune cell types by Stolpe, Anja Van De, Inda, Marcia Alves de, Biezen-Timmermans, Eveline den, Holtzer, Laurent, Ooijen, Henk van, Verhaegh, Wim

“…Abstract To improve pathophysiology research, biomarker discovery and drug development, cell culture models should adequately mimic human (patho)physiology and…”
Get full text

Heterogeneity in signaling pathway activity within primary breast cancer and between primary and metastases by Verhaegh, Wim, van Brussel, Anne, Moelans, Cathy, Alves de Inda, Marcia, Gil, Julie, Bikker, Jan Willem, den Biezen-Timmermans, Eveline, Van De Stolpe, Anja, van Diest, Paul J.

“…Abstract only 589 Background: Treatment with targeted drugs aims to block tumor driving signaling pathway(s). Drug choice is often based on a single…”
Get full text

Abstract 1331: First results of the EIT PACMAN Study: OncoSignal pathway analysis to identify clinically actionable signal transduction pathway activity in a variety of cancer types by Martin-Romano, Patricia, Neerken, Sieglinde, Van de Stolpe, Anja, Den Biezen-Timmerman, Eveline, Ngo, Maud, Nicotra, Claudio, Akse, Martijn, Eggermont, Alexander, Van de Wiel, Paul, Massard, Christophe, Calvo, Fabien

“…Abstract Introduction: Precision medicine has shown to improve outcomes of cancer patients by identifying oncogenic alterations and actionable mutations. Yet,…”
Get full text

Abstract 4261: Development of quantitative multi-platform tests for easy readout of AR, ER, PI3K and MAPK pathway activity to unravel pathophysiology across cancer and tissue types by Akse, Martijn, van Ooijen, Henk, Pierik, Anke, van den Bosch, Sandra, van Zon, Hans, Holtzer, Laurent, van Brussel, Anne, Inda, Márcia, Wesseling-Rozendaal, Yvonne, Verhaegh, Wim, den Biezen-Timmermans, Eveline

“…Abstract Introduction: Currently, the selection of targeted therapy is commonly based on genetic data, such as well-known gene mutations, but these mutations…”
Get full text

EIT PACMAN Study preliminary results: OncoSignal pathway analysis identifies actionable cancer targets by Martin, Patricia, Neerken, Sigi, Van De Stolpe, Anja, den Biezen-Timmermans, Eveline, Akse, Martijn, Ngocamus, Maud, Nicotra, Claudio, Eggermont, Alexander M., Van De Wiel, Paul, Massard, Christophe, Calvo, Fabien M.

“…Abstract only e15606 Background: Precision medicine refers to tailoring of treatment to each individual patient, although identifying tumor driving signaling…”
Get full text

Validation of cAMP phosphodiesterase-4D7 (PDE4D7) for its independent contribution to risk stratification in a prostate cancer patient cohort with longitudinal biological outcomes by Rijntjes, Jos, Alves de Inda, Marcia, van Strijp, Dianne, den Biezen-Timmermans, Eveline, van Brussel, Anne, Wrobel, Janneke, van Zon, Hans, Vos, Pieter, Baillie, George S, Tennstedt, Pierre, Schlomm, Thorsten, Houslay, Miles, Bangma, Chris H., Heinzer, Hans, Hoffmann, Ralf

“…Abstract only 5069 Background: In this study we present the retrospective validation of the prognostic prostate cancer biomarker PDE4D7 in predicting…”
Get full text

Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes by Alves de Inda, Marcia, van Strijp, Dianne, den Biezen-Timmermans, Eveline, van Brussel, Anne, Wrobel, Janneke, van Zon, Hans, Vos, Pieter, Baillie, George S, Tennstedt, Pierre, Schlomm, Thorsten, Houslay, Miles D, Bangma, Chris, Hoffmann, Ralf

“…Abstract Background The clinical metrics used to date to assess the progression risk of newly diagnosed prostate cancer patients only partly represent the true…”
Get full text